Roche Canada invests $2+ million in Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo)

Toronto, ON – April 3, 2019 – The Multiple Sclerosis Society of Canada, Brain Canada Foundation, and Biogen Canada are pleased to announce the addition of Hoffmann-La Roche Limited (Roche Canada) and its contribution of $2.125 million to the Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo). This brings the total amount awarded for the project to over $9 million, which will be used to help people living with and affected by MS in Canada.

Read more